- Detailed Results of Positive Phase 2 Trial of RPC1063 in Ulcerative Colitis to be Presented on February 21, 2015 -
- Company to Host Investor Call and Webcast on February 23, 2015 -
SAN DIEGO, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq: RCPT ), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that data from TOUCHSTONE, the Company's Phase 2 trial of RPC1063 in ulcerative colitis (UC), will be reviewed in an oral podium presentation at the ECCO conference on February 21, 2015 in Barcelona, Spain. ECCO is the largest annual meeting of the European Crohn's and Colitis Organization. The data will be presented by Dr. William Sandborn, Principal Investigator of the trial, Chief of the Division of Gastroenterology and Director of the UC San Diego IBD Center. Details are as follows:
Saturday, February 21, 2015, 9:40 a.m.
Session: New Therapies and Strategies
Plenary Hall, Ground level
CCIB, Plaça de Willy Brandt, 11-14, 08019 Barcelona
Abstract Number: A-1273
In addition, Receptos will host a teleconference and webcast to discuss the results in further detail on Monday, February 23 at 8:30 a.m. ET. The live call may be accessed by phone by calling (866) 757-6808 (domestic) or (760) 536-5211 (international), participant code 90131024. The webcast can be accessed live on the Investor Relations section of the Receptos website at www.receptos.com and will be archived for 14 days following the call. A replay of the call will be available by phone by calling (855) 859-2056, participant code 90131024.
About RPC1063
RPC1063 is a novel, oral, once daily, selective sphingosine 1-phosphate 1 and 5 receptor modulator in development for autoimmune indications including relapsing multiple sclerosis (RMS) and ulcerative colitis (UC). In a Phase 2 trial in patients with RMS, RPC1063 achieved the primary endpoint of reduction in MRI brain lesion activity as well as secondary endpoints measuring effects on other MRI parameters. The overall safety profile of RPC1063 was consistent with the results of prior trials and continues to demonstrate differentiation against other oral agents for treatment of RMS. Receptos is now conducting a Phase 3 clinical development program comprised of two trials: RADIANCE and SUNBEAM, both of which are randomized, double-blind studies designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon beta-1a (Avonex®) in patients with RMS.
RPC1063 is also being studied in inflammatory bowel disease (IBD). The TOUCHSTONE Phase 2 trial of RPC1063 in UC met its primary endpoint and all secondary endpoints with statistical significance in patients on the 1 mg dose of RPC1063 in the 8-week induction period. The overall safety and tolerability profile of RPC1063 was consistent with the results of the RADIANCE Phase 2 trial in RMS, and continues to support the potential for orally administered RPC1063 to significantly improve the treatment paradigm for UC patients. The maintenance period of the TOUCHSTONE trial is currently ongoing. Receptos plans to initiate a Phase 3 program in UC and a Phase 2 program in Crohn's disease in 2015.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune indications including RMS and IBD. Patents supporting RPC1063 were exclusively licensed to Receptos from The Scripps Research Institute (TSRI). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for eosinophilic esophagitis (EoE), an allergic/immune-mediated orphan disease.
Media and Investor Contact: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708
